PL2841431T3 - Dihydrat związku benzotiofenu i sposób jego wytwarzania - Google Patents

Dihydrat związku benzotiofenu i sposób jego wytwarzania

Info

Publication number
PL2841431T3
PL2841431T3 PL13722129T PL13722129T PL2841431T3 PL 2841431 T3 PL2841431 T3 PL 2841431T3 PL 13722129 T PL13722129 T PL 13722129T PL 13722129 T PL13722129 T PL 13722129T PL 2841431 T3 PL2841431 T3 PL 2841431T3
Authority
PL
Poland
Prior art keywords
dihydrate
producing
same
benzothiophene compound
benzothiophene
Prior art date
Application number
PL13722129T
Other languages
English (en)
Inventor
Hiroshi Yamashita
Tetsuya Sato
Takuya Minowa
Yusuke Hoshika
Hidekazu Toyofuku
Tatsuya Yamaguchi
Masahiro Sota
Shuuji Kawano
Takayuki Nakamura
Ryohei Eto
Takuma Ikebuchi
Kei Moriyama
Nobuaki Ito
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2841431(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Publication of PL2841431T3 publication Critical patent/PL2841431T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
PL13722129T 2012-04-23 2013-04-23 Dihydrat związku benzotiofenu i sposób jego wytwarzania PL2841431T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636920P 2012-04-23 2012-04-23
US201361791378P 2013-03-15 2013-03-15
EP13722129.7A EP2841431B2 (en) 2012-04-23 2013-04-23 Dihydrate of benzothiophene compound and process for producing the same

Publications (1)

Publication Number Publication Date
PL2841431T3 true PL2841431T3 (pl) 2017-06-30

Family

ID=48428584

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13722129T PL2841431T3 (pl) 2012-04-23 2013-04-23 Dihydrat związku benzotiofenu i sposób jego wytwarzania

Country Status (37)

Country Link
US (5) US9499525B2 (pl)
EP (1) EP2841431B2 (pl)
JP (1) JP5952917B2 (pl)
KR (1) KR102160395B1 (pl)
CN (1) CN104254530B (pl)
AR (1) AR090774A1 (pl)
AU (1) AU2013253372B2 (pl)
BR (1) BR112014026424B1 (pl)
CA (1) CA2870000C (pl)
CO (1) CO7111315A2 (pl)
CY (1) CY1119103T1 (pl)
DK (1) DK2841431T4 (pl)
EA (1) EA026541B1 (pl)
ES (1) ES2617881T5 (pl)
FI (1) FI2841431T4 (pl)
HK (1) HK1203073A1 (pl)
HR (1) HRP20170242T4 (pl)
HU (1) HUE031997T2 (pl)
IL (1) IL235044B (pl)
IN (1) IN2014DN08867A (pl)
JO (1) JO3325B1 (pl)
LT (1) LT2841431T (pl)
ME (1) ME02619B (pl)
MX (1) MX361723B (pl)
MY (1) MY170220A (pl)
NZ (1) NZ630260A (pl)
PH (1) PH12014502324A1 (pl)
PL (1) PL2841431T3 (pl)
PT (1) PT2841431T (pl)
RS (1) RS55742B2 (pl)
SG (1) SG11201406790VA (pl)
SI (1) SI2841431T2 (pl)
SM (1) SMT201700130B (pl)
TW (1) TWI562991B (pl)
UA (1) UA117456C2 (pl)
WO (1) WO2013162046A1 (pl)
ZA (1) ZA201407477B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
US20170042887A1 (en) 2014-04-22 2017-02-16 Otsuka Pharmaceutical. Co., Ltd. Combination of Brexpiprazole and Nalmefene and Use Thereof for Treating Substance-Related Disorders
CN104447723A (zh) * 2014-11-28 2015-03-25 瑞阳制药有限公司 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
CN106883223B (zh) * 2015-12-16 2021-11-23 北京福元医药股份有限公司 一种Brexpiprazole盐酸盐的纯化方法
WO2017106641A1 (en) 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
US10464931B2 (en) 2015-12-28 2019-11-05 Honour (R&D) Process for the preparation of Quinolin-2(1H)-one derivatives
JP2019059672A (ja) * 2015-12-28 2019-04-18 大日本住友製薬株式会社 治療抵抗性うつ病等の治療薬
WO2017134038A1 (en) 2016-02-01 2017-08-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole dihydrate for use in intramuscular injectable sustained release formulations
US20170320862A1 (en) 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
CN107365305A (zh) * 2016-05-12 2017-11-21 上海奥博生物医药技术有限公司 一种依匹哌唑新晶型及其制备方法
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
CN106188023A (zh) * 2016-07-04 2016-12-07 山东川成医药股份有限公司 一种依匹唑派的精制方法
PL233778B1 (pl) 2016-07-19 2019-11-29 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu
US20200093821A1 (en) 2016-08-16 2020-03-26 Hexal Ag Pharmaceutical Compositions of a Benzothiophene Compound
EP3500247B1 (en) 2016-08-16 2020-05-27 H e x a l Aktiengesellschaft Immediate release tablet of a benzothiophene compound
CN107936005A (zh) * 2016-10-13 2018-04-20 上海科胜药物研发有限公司 一种依匹哌唑新晶型ii及其制备方法
CN111233848A (zh) * 2016-12-14 2020-06-05 上海博志研新药物技术有限公司 一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用
US11072605B2 (en) 2017-02-02 2021-07-27 Hexal Ag Crystalline brexpiprazole
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
CN111440158A (zh) * 2020-03-24 2020-07-24 石药集团中奇制药技术(石家庄)有限公司 一种盐酸依匹哌唑新晶型及其制备方法
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
WO2023067664A1 (ja) * 2021-10-18 2023-04-27 大塚製薬株式会社 ベンゾチオフェン化合物の新規結晶形及びその製造方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ZA200602347B (en) 2003-10-23 2007-09-26 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
WO2006030446A1 (en) 2004-09-13 2006-03-23 Matrix Laboratories Ltd Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
PE20090387A1 (es) * 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
EP2214483B1 (en) * 2007-10-26 2012-06-20 Repligen Corporation Methods of identifying histone deacetylase inhibitors useful for neurological disorders
MX2010008365A (es) * 2008-01-30 2010-08-23 Novartis Ag Formulacion de liberacion sostenida que comprende octreotido y tres polimeros lineales de polilactido-co-glicolido.
ES2685469T3 (es) 2010-08-24 2018-10-09 Otsuka Pharmaceutical Co., Ltd. Suspensión y composición de torta que contienen derivado de carboestirilo y aceite de silicona y/o derivado de aceite de silicona
JP2012232958A (ja) * 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd 注射製剤
BR112014001520B1 (pt) * 2011-07-28 2022-05-10 Otsuka Pharmaceutical Co., Ltd Processo para a produção de composto de benzo[b]tiofeno
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
AR090775A1 (es) 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Also Published As

Publication number Publication date
FI2841431T4 (fi) 2024-04-18
US20210115030A1 (en) 2021-04-22
EP2841431B2 (en) 2024-01-24
LT2841431T (lt) 2017-03-27
HRP20170242T1 (hr) 2017-04-07
HK1203073A1 (en) 2015-10-16
EA201491933A1 (ru) 2015-03-31
JP5952917B2 (ja) 2016-07-13
SG11201406790VA (en) 2014-11-27
US20230049327A1 (en) 2023-02-16
JO3325B1 (ar) 2019-03-13
RS55742B1 (sr) 2017-07-31
IL235044B (en) 2019-05-30
BR112014026424B1 (pt) 2022-09-13
PT2841431T (pt) 2017-03-07
MX2014012527A (es) 2015-03-19
TW201348229A (zh) 2013-12-01
HRP20170242T8 (hr) 2017-09-22
HUE031997T2 (en) 2017-08-28
BR112014026424A2 (pt) 2017-06-27
DK2841431T4 (da) 2024-02-12
CA2870000C (en) 2021-02-16
US10407415B2 (en) 2019-09-10
US20200140424A1 (en) 2020-05-07
JP2015514677A (ja) 2015-05-21
IN2014DN08867A (pl) 2015-05-22
ES2617881T3 (es) 2017-06-20
EP2841431B1 (en) 2017-01-04
US20170066752A1 (en) 2017-03-09
KR20150013189A (ko) 2015-02-04
ES2617881T5 (es) 2024-05-22
SI2841431T1 (sl) 2017-03-31
CN104254530A (zh) 2014-12-31
ME02619B (me) 2017-06-20
ZA201407477B (en) 2015-12-23
NZ630260A (en) 2015-09-25
UA117456C2 (uk) 2018-08-10
EA026541B1 (ru) 2017-04-28
WO2013162046A1 (en) 2013-10-31
EP2841431A1 (en) 2015-03-04
PH12014502324B1 (en) 2015-01-12
US20150087655A1 (en) 2015-03-26
AR090774A1 (es) 2014-12-03
SMT201700130B (it) 2017-03-08
HRP20170242T4 (hr) 2024-03-01
AU2013253372B2 (en) 2016-12-08
CY1119103T1 (el) 2018-02-14
RS55742B2 (sr) 2024-04-30
IL235044A0 (en) 2014-12-31
MX361723B (es) 2018-12-14
TWI562991B (en) 2016-12-21
DK2841431T3 (en) 2017-03-06
MY170220A (en) 2019-07-10
AU2013253372A1 (en) 2014-10-30
SI2841431T2 (sl) 2024-03-29
CO7111315A2 (es) 2014-11-10
PH12014502324A1 (en) 2015-01-12
CN104254530B (zh) 2016-09-21
KR102160395B1 (ko) 2020-09-28
CA2870000A1 (en) 2013-10-31
US9499525B2 (en) 2016-11-22

Similar Documents

Publication Publication Date Title
FI2841431T4 (fi) Bentsotiofeeniyhdisteen dihydraatti ja menetelmä sen tuottamiseksi
EP2552874A4 (en) PROCESS FOR PREPARING HEXAFLUOR-2 BUTENE
PT2875062T (pt) Processo de síntese de poliarilétercetonas
SG10201703051WA (en) Compounds and methods for the production of suckerin and uses thereof
EP2558432A4 (en) METHOD FOR THE PRODUCTION OF TETRAFLUOROLEFINES
HK1205097A1 (en) Process for the production of methylbutinol
IL226677A (en) Beta-amyloid production compounds
PL399420A1 (pl) Sposób wytwarzania dihydrochalkonu
IL236450A0 (en) Process for the preparation of 5-fluoro-h1-pyrazoles
PL399418A1 (pl) Sposób wytwarzania 4-metoksydihydrochalkonu
PL399419A1 (pl) Sposób wytwarzania 4-metoksydihydrochalkonu
PL399421A1 (pl) Sposób wytwarzania dihydrochalkonu
SI2828396T1 (sl) Postopek za pripravo G-CSF
HK1210225A1 (en) Procedure for the production of tiacumicin
IL229326A (en) Process for making n-iodine-affluent
ZA201405824B (en) Process for the preparation of substituted phenylpropanones
HU229987B1 (en) Process for the preparation of pyrimidinyl-piperazines
PL398696A1 (pl) Sposób wytwarzania dihydrochalkonu